Welcome to our dedicated page for CORCEPT THERAPEUTICS SEC filings (Ticker: CORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Corcept Therapeutics (CORT) insider filing under Rule 144 reports a proposed sale of 20,000 common shares through Stifel Nicolaus & Co., with an aggregate market value of $1,662,200 and an approximate sale date of 10/01/2025. The filing states the 20,000 shares were acquired via a stock option exercise and paid in cash on 10/01/2025. The filer also disclosed multiple prior open-market sales by the same person over the past three months totaling 62,000 shares with gross proceeds reported for each trade. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
CORCEPT THERAPEUTICS INC (CORT) Form 144 filing reports a proposed sale of 5,000 common shares through Stifel Nicolaus & Co. with an aggregate market value of $415,550.00, planned for 10/01/2025 on NASDAQ. The filing states these 5,000 shares were acquired the same day (10/01/2025) by stock option exercise and paid in cash.
The filing also lists prior sales by the same person, Joseph D. Lyon, totaling 15,000 shares sold on 07/01/2025, 07/17/2025, 07/18/2025, 08/01/2025, and 09/02/2025 with reported gross proceeds for each transaction. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), reported a transaction dated 09/19/2025. The Form 4 shows a disposition of 200 shares of Common Stock coded as G(1) at a price of $0, with an explanatory note that the shares were donated to a Fidelity Charitable Giving Account. Following the reported transaction, the reporting person beneficially owned 5,287 shares. The form is signed by an attorney-in-fact and cites a power of attorney on file with the SEC.
Gillian M. Cannon, a director of Corcept Therapeutics Inc. (CORT), reported a donation of 7,393 shares of the issuer's common stock executed on 09/10/2025 under transaction code G(1). The filing shows the shares were donated to a Fidelity Charitable Giving Account and the reporting person’s beneficial ownership of common stock following the transaction is reported as 0 shares. The Form 4 was signed by an attorney-in-fact, Joseph Douglas Lyon, on 09/11/2025. The filing includes a remark that the power of attorney is on file with the SEC.
Daniel N. Swisher Jr., a director of Corcept Therapeutics, executed transactions on 09/10/2025 under a 10b5-1 plan adopted August 1, 2024. He exercised 2,200 stock options with an exercise price of $14.08 and simultaneously sold the resulting 2,200 common shares at $72.45. Following the transactions, the Form 4 reports 0 shares of common stock beneficially owned from the sold shares. The filing also shows the exercised options were fully exercisable and references remaining derivative holdings totaling 3,300 (as reported in the derivative table). The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Form 144 notice for Corcept Therapeutics, Inc. (CORT) discloses a proposed sale of 2,200 common shares to be executed on 09/10/2025 through Fidelity Brokerage Services (NASDAQ). The filing lists an aggregate market value of $159,390 and reports 105,371,729 shares outstanding. The shares were acquired under an option granted 08/20/2018 and the reported payment method is cash. The filer, identified in past sales as Daniel Swisher, sold three prior blocks of 2,200 shares each on 06/10/2025, 07/10/2025 and 08/11/2025, with gross proceeds shown for each sale. Remarks and signature attestations are present but no additional explanatory text or plan-adoption date is provided.
Corcept Therapeutics filed a report stating that the U.S. Food and Drug Administration has accepted its New Drug Application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer. This acceptance means the FDA has agreed to review the application for this potential new therapy.
Gillian M. Cannon, a director of Corcept Therapeutics (CORT), executed option activity on 09/04/2025. She exercised 11,000 stock options at an exercise price of $22.99 per share and received 11,000 shares. To cover the exercise cost in a net (cashless) exercise, 3,607 shares were withheld at an implied price of $70.13, leaving 7,393 shares issued to her from that portion. Following these transactions, the filing reports 11,000 common shares directly owned from the exercise and 49,000 derivative securities (stock options) beneficially owned and fully exercisable through their stated expiration date of 12/01/2030.
William Guyer, Chief Development Officer of Corcept Therapeutics (CORT), reported multiple transactions dated 09/02/2025. The filing shows an acquisition of 20,000 common shares and contemporaneous sales of 15,594 and 4,406 common shares at weighted-average prices of $70.392 and $70.8478, respectively, for total shares sold of 20,000. The sales were made pursuant to a 10b5-1 trading plan adopted on 11/27/2024. The report also records a transaction in a derivative security: 20,000 stock options with a $21.65 exercise/conversion price and noted as fully exercisable, and the filing indicates 330,000 derivative securities beneficially owned following the transaction. Following these trades, Mr. Guyer beneficially owns 25,487 common shares directly.
Corcept Therapeutics (CORT) insider Joseph D. Lyon, Chief Accounting & Technology Officer, reported multiple transactions on 09/02/2025 and 09/03/2025. He exercised a stock option with a $13.56 strike for 5,000 shares on 09/02/2025, increasing derivative-based beneficial ownership to 26,571 shares. On the same day he sold a total of 5,000 shares under a 10b5-1 plan (weighted average sale prices noted at $70.2386 and $70.7571), purchased 200 shares under the company Purchase Plan at the closing price ($71.38), received 200 restricted shares at $0 under the Purchase Plan, and had 189 shares withheld to satisfy tax withholding upon vesting. The reporting person adopted the 10b5-1 plan on 08/30/2024. All reported holdings are direct.